Latest Headlines

Latest Headlines

Valeant rolls out prelim data on its newly purchased cancer vaccine Provenge

Valeant only just picked up Provenge from bankrupt Dendreon, but it's already trumpeting positive data for the flailing prostate cancer vaccine.

Can Valeant turn Dendreon's flailing Provenge into a viable cancer competitor?

The deadline to bid for Dendreon has come and gone, and now that no other qualified bids have come forward, Valeant is walking away victorious.

Valeant forays into oncology with stalking-horse bid for Dendreon's Provenge

Valeant has finally made a significant M&A move after its failed pursuit of Allergan, and bankrupt Dendreon has finally found a way to unload cancer vaccine Provenge. And they're one and the same.

For sale: Bankrupt Dendreon and its laggard Provenge, for $275M or more. Any takers?

Struggling Dendreon has tried streamlining its manufacturing process for cancer vaccine Provenge. It's tried laying off hundreds of employees, cutting operating costs and raising capital. And it's tried putting itself up for sale. But no dice: The company is still swimming in a sea of debt that Monday spurred it to file for Chapter 11 bankruptcy protection.

J&J oncology vet takes the helm at foundering Dendreon

Struggling Dendreon has named a new CEO in W. Thomas Amick, a longtime Johnson & Johnson vet.

UPDATED: Shaky Dendreon loses its CEO as debt payments loom

Looks like CEO John Johnson won't be around to go down with Dendreon if the ship sinks. Johnson resigned from the board last week and will give up his CEO post in mid-August, the company said Monday.

Valeant sales rise on deals; Regeneron's Eylea falls short; Dendreon, Ariad aided by cost cuts

From a slight rise in revenue at the struggling cancer drugmaker Dendreon to a deal-fed increase at Valeant Pharmaceuticals to an against-the-odds upward tick at Germany's Stada, some smaller drugmakers are thumbing their noses at Big Pharma's downward trend this quarter.

SEC: Provenge critic lied about her bets Dendreon stock would fall

Dendreon's lead treatment, prostate cancer vaccine Provenge, continues to post sales losses, leaving many pessimistic that the struggling biotech will be able to right the ship. Now, however, it appears one of the company's doubters may have had an ulterior motive.

For-sale Dendreon slashes 150 jobs, cuts more costs in hunker-down move

Dendreon's press releases have a definite broken-record sound. After posting another round of disappointing sales and earnings, the company is once again cutting jobs and costs. This time, it's 15% of the workforce, or about 150 jobs, and $125 million in spending.

Dendreon's for sale. Will anyone step up to battle for Provenge?

Just a few days ago, we learned that Dendreon is looking to woo a buyer. The question now is whether the struggling drugmaker can find a suitor to take on its baggage.